Dyve Biosciences

Dyve Biosciences utilizes its proprietary DMAX transdermal platform to deliver pH-modulating agents for the treatment of immunologic and oncologic diseases. The company focuses on targeting acidic microenvironments within these disease areas to enhance therapeutic outcomes. Dyve’s lead products, DYV800 and DYV700, are designed to address these acidic conditions. DYV800 aims to raise the pH of acidic tumor microenvironments to inhibit tumor proliferation, while DYV700, which has completed a successful Phase 2 study in 2022, is pivotal-trial ready for treating acute gout by reducing pain in acute gouty arthritis. Additionally, DYV024 is in the preclinical stage for treating psoriasis. The DMAX platform allows for the transdermal delivery of pH-modulating agents and other molecules that are unsuitable for oral or injectable delivery, potentially improving the therapeutic benefits of a wide array of approved therapies. Dyve Biosciences has been active in the scientific community, presenting preclinical data for DYV800 at the American Association for Cancer Research 2023 Annual Meeting and participating in various conferences such as the BIO International Convention, the 34th Annual Roth Conference, the UBS Global Healthcare Conference, and the Biocom California Global Life Science Partnering Conference. The company also announced a research and development collaboration with Moffitt Cancer Center in February 2022 and hosted a key opinion leader webinar on gout and DYV702 in November 2021. Dyve Biosciences received FDA clearance to begin a Phase 2 study of DYV700 for acute gout pain in December 2019 and announced positive results from a pilot study in gout pain at the European Crystal Network Workshop 2019.